FCN-411

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameFCN-411
Drug Alias NameFCN-411
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR L858R inhibitorsEGFR T790M inhibitorsEpidermal growth factor receptor erbB1 inhibitors +[5] 
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Receptor protein-tyrosine kinase erbB-4 +[5] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Fosun Pharmaceutical (Group) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFochon Pharmaceuticals Ltd
Inactive CompaniesAhon Pharmaceutical Co Ltd
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsLung Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A